According to Zacks, “Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut. “
Separately, ValuEngine raised Trevi Therapeutics from a hold rating to a buy rating in a research note on Tuesday, March 3rd.
Shares of TRVI opened at $6.87 on Friday. The business’s 50 day moving average is $4.01 and its 200 day moving average is $3.98. The company has a market capitalization of $107.90 million and a PE ratio of -4.02. Trevi Therapeutics has a 12-month low of $1.33 and a 12-month high of $8.05.
Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, May 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.04). On average, equities research analysts predict that Trevi Therapeutics will post -2.11 EPS for the current year.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Read More: What does a market perform rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.